Gastroenterology

Gastroenterology

Volume 149, Issue 1, July 2015, Pages 25-28
Gastroenterology

Editorial
Direct-Acting Antivirals Cure Innate Immunity in Chronic Hepatitis C

https://doi.org/10.1053/j.gastro.2015.05.026Get rights and content

References (23)

  • T. Pembroke et al.

    Rapid early innate control of hepatitis C virus during IFN-α treatment compromises adaptive CD4+ T-cell immunity

    Eur J Immunol

    (2012)
  • Cited by (15)

    • Modeling indicates efficient vaccine-based interventions for the elimination of hepatitis C virus among persons who inject drugs in metropolitan Chicago

      2019, Vaccine
      Citation Excerpt :

      However, among PWID attaining SVR following antiviral treatment, most remain susceptible to the development of chronic HCV infections following reinfection [14]. Indeed, while functional CD4+ and CD8+ T-cell responses have been shown in patients following early DAA treatment of acute phase HCV infections, such T-cell responses are absent or weak in patients successfully treated with DAA during the chronic phase [15,16]. Therefore, following treatment, risk reduction methods are necessary to reduce the reinfection of PWID [17,18].

    • Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56<sup>bright</sup> NK cells

      2017, Journal of Hepatology
      Citation Excerpt :

      Of note, IL-18BPa serum levels were also increased in patients that did not respond to the old pegylated IFNα-ribavirin treatment. The therapeutic effect of this treatment on innate immunity is entirely different from that observed with the new direct-acting antivirals57 and essentially relies on the functional efficiency of NK cells.58 Thus, it is plausible that the inefficiency of the IL-18 axis contributes to lack of response to IFNα-based therapies.

    • Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity

      2017, Journal of Hepatology
      Citation Excerpt :

      This study has important translational implications, as it provides clear evidence that virus-induced NK cell activation not only impairs IFN-γ production but also alters the efficiency of ADCC in chronic HCV infection. The potent DAAs currently available in the market have the ability to restore innate and adaptive immunity to HCV by reducing NK and T cell activation [51–53]. Return to steady-state immunity is an important step towards recovery.

    • Control of HCV infection by natural killer cells and macrophages

      2020, Cold Spring Harbor Perspectives in Medicine
    View all citing articles on Scopus

    Conflicts of interest The author discloses no conflicts.

    View full text